The association of body mass index and prostate-specific antigen in a population-based study

Jacques Baillargeon, Bradley H Pollock, Alan R. Kristal, Patrick Bradshaw, Javier Hernandez, Joseph Basler, Betsy Higgins, Steve Lynch, Thomas Rozanski, Dean Troyer, Ian Thompson

Research output: Contribution to journalArticle

195 Scopus citations


BACKGROUND. Recent studies of men with prostate carcinoma suggest that obesity may be associated with more advanced-stage disease and lower overall survival rates. One possible link between body mass index (BMI) and prostate carcinoma prognosis may be disease ascertainment. Prostate-specific antigen (PSA) is widely used to screen for prostate carcinoma. METHODS. The authors examined the association between BMI and PSA in a population-based study of 2779 men without prostate carcinoma. Between 2001 and 2004, these men were enrolled in a study sponsored by the San Antonio Center of Biomarkers of Risk, a clinical and epidemiologic center of the Early Detection Research Network of the National Cancer Institute. RESULTS. The mean PSA value decreased in a linear fashion with an increase in BMI category, from 1.01 ng/mL in normal weight men to 0.69 ng/mL in obese (Class III) men, after adjusting for race/ethnicity and age. CONCLUSIONS. Lower levels of PSA in obese and overweight men could mask biologically consequential prostate carcinoma.

Original languageEnglish (US)
Pages (from-to)1092-1095
Number of pages4
Issue number5
StatePublished - Mar 1 2005
Externally publishedYes



  • Body mass index
  • Cancer risk
  • Prostate carcinoma
  • Prostate-specific antigen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Baillargeon, J., Pollock, B. H., Kristal, A. R., Bradshaw, P., Hernandez, J., Basler, J., Higgins, B., Lynch, S., Rozanski, T., Troyer, D., & Thompson, I. (2005). The association of body mass index and prostate-specific antigen in a population-based study. Cancer, 103(5), 1092-1095.